
Anthony Hagen
Advertisement
Articles by Anthony Hagen


The FDA will reassess 6 indications for immune checkpoint inhibitors that were granted accelerated approval but failed to prove clinical benefit in confirmatory trials.

Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Emerging Threats to Cell and Gene Therapy Access
2
FDA Approves Oral Giredestrant Regimen for ESR1-Mutated Breast Cancer
3
FDA Grants Accelerated Approval to Neladalkib for Previously Treated ALK-Positive NSCLC
4
FDA Approves Secukinumab as First Anti–IL-17 Biologic for PMR
5
